| Titolo |
Pubblicato in |
Anno |
| Preclinical and clinical study on type 3 metabotropic glutamate receptors in Parkinson's disease |
NPJ PARKINSON'S DISEASE |
2025 |
| The Story behind the Mask: A Narrative Review on Hypomimia in Parkinson’s Disease |
BRAIN SCIENCES |
2024 |
| Metabotropic Glutamate Receptors Type 3 and 5 Feature the “NeuroTransmitter-type” of Glioblastoma: A Bioinformatic Approach |
CURRENT NEUROPHARMACOLOGY |
2024 |
| Effects of levodopa/carbidopa intestinal gel infusion on autonomic symptoms in advanced Parkinson’s disease: a systematic review |
CLINICAL AUTONOMIC RESEARCH |
2024 |
| Pharmacological Blockade of Group II Metabotropic Glutamate Receptors Reduces the Incidence of Brain Tumors Induced by Prenatal Exposure to N-ethyl-N-nitrosourea in Rats |
CURRENT NEUROPHARMACOLOGY |
2024 |
| Age at Onset Influences Progression of Motor and Non-Motor Symptoms during the Early Stage of Parkinson’s Disease: A Monocentric Retrospective Study |
BRAIN SCIENCES |
2023 |
| Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings |
NEURAL REGENERATION RESEARCH |
2023 |
| Four Days Are Enough to Provide a Reliable Daily Step Count in Mild to Moderate Parkinson’s Disease through a Commercial Smartwatch |
SENSORS |
2023 |
| Up-regulation of the Trace Amine Receptor, TAAR-1, in the Prefrontal Cortex of Individuals Affected by Schizophrenia |
SCHIZOPHRENIA BULLETIN |
2023 |
| Blunted type-5 metabotropic glutamate receptor-mediated polyphosphoinositide hydrolysis in two mouse models of monogenic autism |
NEUROPHARMACOLOGY |
2023 |
| Feasibility, Safety, and Effectiveness of Telerehabilitation in Mild-to-Moderate Parkinson's Disease |
FRONTIERS IN NEUROLOGY |
2022 |
| Monoamine-Oxidase type B- Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action |
CURRENT NEUROPHARMACOLOGY |
2022 |
| Step-Counting Accuracy of a Commercial Smartwatch in Mild-to-Moderate PD Patients and Effect of Spatiotemporal Gait Parameters, Laterality of Symptoms, Pharmacological State, and Clinical Variables |
SENSORS |
2022 |
| Switch from rasagiline to safinamide in fluctuating Parkinson’s disease patients. a retrospective, pilot study |
NEUROLOGICAL RESEARCH |
2021 |
| Validation of the Canadian occupational performance measure in Italian Parkinson’s disease clients |
PHYSICAL & OCCUPATIONAL THERAPY IN GERIATRICS |
2021 |
| The bacterial quorum sensing molecule, 2-heptyl-3-hydroxy-4-quinolone (PQS), inhibits signal transduction mechanisms in brain tissue and is behaviorally active in mice |
PHARMACOLOGICAL RESEARCH |
2021 |
| Drugs used in the treatment of multiple sclerosis during COVID-19 pandemic: a critical viewpoint |
CURRENT NEUROPHARMACOLOGY |
2021 |
| Drug Choices and Advancements for Managing Depression in Parkinson`s Disease |
CURRENT NEUROPHARMACOLOGY |
2020 |
| The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study |
AGING CLINICAL AND EXPERIMENTAL RESEARCH |
2020 |
| Different generations of type-b monoamine oxidase inhibitors in parkinson’s disease: From bench to bedside |
CURRENT NEUROPHARMACOLOGY |
2019 |
